IRIS
DE TURSI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.860
EU - Europa 2.849
AS - Asia 1.683
SA - Sud America 207
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 12
OC - Oceania 3
Totale 8.633
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.835
SG - Singapore 777
IE - Irlanda 671
IT - Italia 599
CN - Cina 481
SE - Svezia 420
UA - Ucraina 262
FR - Francia 217
DE - Germania 198
BR - Brasile 188
TR - Turchia 177
GB - Regno Unito 167
IN - India 115
RU - Federazione Russa 89
FI - Finlandia 65
VN - Vietnam 48
BE - Belgio 44
HK - Hong Kong 38
AT - Austria 31
CZ - Repubblica Ceca 19
PL - Polonia 17
CA - Canada 16
NL - Olanda 14
EU - Europa 11
JP - Giappone 11
BD - Bangladesh 9
EG - Egitto 7
LT - Lituania 6
RO - Romania 6
ES - Italia 5
GR - Grecia 5
IQ - Iraq 5
PT - Portogallo 5
AR - Argentina 4
MA - Marocco 4
MX - Messico 4
PK - Pakistan 4
CO - Colombia 3
PY - Paraguay 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AU - Australia 2
CL - Cile 2
EC - Ecuador 2
ID - Indonesia 2
PE - Perù 2
TW - Taiwan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DZ - Algeria 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KE - Kenya 1
KR - Corea 1
LB - Libano 1
LV - Lettonia 1
MM - Myanmar 1
MT - Malta 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PR - Porto Rico 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.633
Salva come PNG Salva come JPEG
Città #
Chandler 877
Dublin 647
Singapore 529
Jacksonville 446
Princeton 262
Ashburn 185
The Dalles 130
Nanjing 124
Chieti 116
Izmir 112
Dearborn 105
Wilmington 105
Southend 104
Altamura 100
Santa Clara 96
Beijing 94
Ann Arbor 89
Pescara 71
Los Angeles 64
Boardman 57
Cambridge 54
New York 52
Dong Ket 47
Brussels 43
Munich 42
Washington 39
Hong Kong 38
Menlo Park 36
Nanchang 30
Shenyang 24
Rome 23
Helsinki 21
Norwalk 21
Nuremberg 20
Falls Church 19
Hebei 19
Woodbridge 19
Kunming 18
Vienna 17
Frankfurt am Main 16
Houston 16
Seattle 16
Tianjin 16
São Paulo 15
Ancona 13
Jiaxing 13
Milan 13
Amsterdam 12
Hangzhou 12
Brno 11
Edinburgh 10
Pune 9
Redwood City 9
Tokyo 9
Grevenbroich 8
Kraków 8
London 8
Boston 7
Cairo 7
Campinas 7
Changchun 7
Chicago 7
Hefei 7
Shanghai 7
Warsaw 7
Changsha 6
Guangzhou 6
Mcallen 6
Phoenix 6
Rio de Janeiro 6
Ascoli Piceno 5
Belo Horizonte 5
Giaveno 5
Lanciano 5
Montreal 5
Moscow 5
Pisa 5
San Francisco 5
Shijiazhuang 5
Simi Valley 5
Tappahannock 5
Toronto 5
Brasília 4
Curitiba 4
Franca 4
L’Aquila 4
Madrid 4
Olomouc 4
Rouen 4
Turku 4
Zhengzhou 4
Altino 3
Ameno 3
Aprilia 3
Athens 3
Atlanta 3
Bangalore 3
Brooklyn 3
Charlotte 3
Chengdu 3
Totale 5.318
Salva come PNG Salva come JPEG
Nome #
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 126
PERITONECTOMIA ED HIPEC NEL TRATTAMENTO DELLA CARCINOSI PERITONEALE: RISULTATI PRELIMINARI DOPO UN ANNO DI ESPERIENZA 119
New Targets for Therapy in Pancreatic Cancer 117
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 115
A multicenter phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary Results 114
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 111
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 110
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 106
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 105
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 104
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 103
PO-1074 Radiotherapy and immuno-check point inhibitors for brain metastases. A mono-institutional analysis 102
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 98
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 98
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 97
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 97
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 96
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 96
Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naive Patients: An Italian Analysis of Patients' Satisfaction 95
Principali effetti collaterali delle terapie mediche 95
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 95
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 95
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 90
null 90
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study 89
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 87
ABIRATERONE ACETATE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHEMOTHERAPY-NAIVE PATIENTS: AN ITALIAN MULTICENTER 'REAL-LIFE' 1-YEAR STUDY 87
Speed rate (SR) as a new dynamic index of melanoma behavior 87
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 87
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 86
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 85
Cytokine Levels and UVr Sensitivity in HaCaT Cells and Cetuximab Treated Patients. 85
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 85
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 84
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 83
Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study 82
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 81
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 80
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 80
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 79
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 79
Rivaroxaban for cancer-associated cardiac thrombosis 77
Skin toxicity evaluation in patients treated with cetuximab for metastatic colorectal cancer: a new tool for more accurate comprehension of quality of life impacts 77
A real-life multicenter, retrospective analysis of Abiraterone Acetate (AA) in 340 metastatic castration-resistant prostate cancer (mCRPC) patients after chemotherapy, updated results 77
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 77
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 76
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 76
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 76
Real world treatment practice in patients with advanced melanoma in the nivolumab era: five novel Italian case reports and a literature review 76
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 75
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 75
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 75
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 75
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 75
Enzalutamide in patients with castration-refractory prostate cancer: Retrospective, multicenter, real life study 75
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 74
Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study 74
Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A “snapshot” from clinical practice 73
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 73
Peritonectomy and hyperthermic chemotherapy in patients with advanced or recurrent ephitelial ovarian cancer: a single center cohort study 72
Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 69
A real -life multicenter study on body weight loss and body mass index in advanced Gastric Cancer patients treated with Ramucirumab-based second -line therapy 69
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 69
F05Relationship and predictive role of the dual expression of FGFR and IL8 in metastatic renal cell carcinoma (mRCC) 68
Relationship and predictive role of the dual expression of FGFR and IL-8 in metastatic renal cell carcinoma treated with targeted agents 68
Enzalutamide in real life: Results from a retrospective, multicenter, italian study 68
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 68
Enzalutamide in patients with castration-resistant prostate cancer: retrospective, multicenter, real life study 68
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 68
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: A dose-finding study 67
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 67
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 67
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 66
Cabazitaxel after Docetaxel in patients with metastatic, castration-resistant, prostate cancer (mCRPC): A prospective, observational study about toxicity profile and quality of life. 66
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes 66
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 66
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 66
Epirubicin plus low-dose trastuzumab in HER2 positivemetastatic breast cancer 65
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 65
null 65
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 65
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 64
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 63
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa study 62
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 61
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 61
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 61
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS) 61
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results 60
Nivolumab and diabetes mellitus: safe administration in a patient with pancreatic metastases from melanoma 58
PO-06 Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 58
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 58
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. 57
Treatment and outcome (s) of a large cohort of Italian patients (pts) with poor-risk metastatic renal cell carcinoma (prRCC) 57
Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP) 57
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC) 54
Epidermal Growth Factor Immunotherapy: Exploring the Effects of NB-UVB Exposure 54
Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients 54
High blood concentration of circulating cancer stem cell-derived extracellular vesicles is associated with poor survival in advanced colorectal cancer patients 54
Management of metastatic renal cell carcinoma patients with poor-risk features: current status and future perspectives. 52
Totale 7.840
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.088
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.088
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202016 0 0 0 0 0 0 0 0 0 0 0 16
2020/2021815 122 28 153 21 51 168 33 24 58 51 30 76
2021/2022803 19 28 14 193 75 26 20 43 51 20 68 246
2022/20232.328 205 323 188 257 166 411 115 216 273 23 103 48
2023/20241.042 63 32 79 34 67 394 177 43 25 35 10 83
2024/20252.154 133 454 303 68 56 125 120 126 256 140 290 83
Totale 9.374